October 9, 2024 12:31 PM EDTUpdated 12:55 PM
FDA+

Cov­er­ing obe­si­ty drugs could cost Medicare $35B by 2034, CBO says

Max Bayer

Pharma Reporter

While Medicare doesn’t cur­rent­ly cov­er an­ti-obe­si­ty drugs, a new re­port from the Con­gres­sion­al Bud­get Of­fice es­ti­mates that cov­er­age could cost Medicare $35 bil­lion from 2026 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

‘Just the be­gin­ning’: No­bel Prizes show the AI era has ar­rived in biotech

AI biotech in­sitro part­ners with Lil­ly on meta­bol­ic dis­ease drugs

Zealand Phar­ma hit with sec­ond CRL for glucagon re­cep­tor ag­o­nist

Cri­net­ics’ $500M of­fer­ing; Boehringer inks deal with macro­cy­cles biotech

Ex­clu­sive Q&A: FDA's prin­ci­pal deputy com­mis­sion­er on tak­ing over for Califf, ad­comms, ac­cel­er­at­ed ap­provals and more

Kevin Tang's Con­cen­tra swoops in on an­oth­er strug­gling biotech, of­fer­ing to buy Kezar

A service from the Financial Times